BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2250 related articles for article (PubMed ID: 18579750)

  • 1. TEAD mediates YAP-dependent gene induction and growth control.
    Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL
    Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein.
    Zhao B; Kim J; Ye X; Lai ZC; Guan KL
    Cancer Res; 2009 Feb; 69(3):1089-98. PubMed ID: 19141641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Abl antagonizes the YAP oncogenic function.
    Keshet R; Adler J; Ricardo Lax I; Shanzer M; Porat Z; Reuven N; Shaul Y
    Cell Death Differ; 2015 Jun; 22(6):935-45. PubMed ID: 25361080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics.
    Foster CT; Gualdrini F; Treisman R
    Genes Dev; 2017 Dec; 31(23-24):2361-2375. PubMed ID: 29317486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mask is required for the activity of the Hippo pathway effector Yki/YAP.
    Sansores-Garcia L; Atkins M; Moya IM; Shahmoradgoli M; Tao C; Mills GB; Halder G
    Curr Biol; 2013 Feb; 23(3):229-35. PubMed ID: 23333314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
    Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into the YAP and TEAD complex.
    Li Z; Zhao B; Wang P; Chen F; Dong Z; Yang H; Guan KL; Xu Y
    Genes Dev; 2010 Feb; 24(3):235-40. PubMed ID: 20123905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
    Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
    Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.
    Liu-Chittenden Y; Huang B; Shim JS; Chen Q; Lee SJ; Anders RA; Liu JO; Pan D
    Genes Dev; 2012 Jun; 26(12):1300-5. PubMed ID: 22677547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition.
    Diepenbruck M; Waldmeier L; Ivanek R; Berninger P; Arnold P; van Nimwegen E; Christofori G
    J Cell Sci; 2014 Apr; 127(Pt 7):1523-36. PubMed ID: 24554433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.
    Lamar JM; Stern P; Liu H; Schindler JW; Jiang ZG; Hynes RO
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2441-50. PubMed ID: 22891335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway.
    Sidor CM; Brain R; Thompson BJ
    Curr Biol; 2013 Feb; 23(3):223-8. PubMed ID: 23333315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
    Xia Y; Zhang YL; Yu C; Chang T; Fan HY
    PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.